Enrollment currently scheduled to begin in Q1 2026 M107 is the first potential disease-modifying drug for the treatment of gastroparesis M107’s mechanism of action has been shown to shift ...
RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics, and its subsidiary, Aclipse Two, Inc (“Aclipse”), an innovative biopharmaceutical company developing life-changing treatments for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results